Prevalence and clinical associations of myositis antibodies in a large cohort of interstitial lung diseases
<h4>Background</h4> Serologic testing for autoantibodies is recommended in interstitial lung diseases (ILDs), as connective tissue diseases (CTDs) are an important secondary cause. Myositis antibodies are associated with CTD-ILD, but clinical associations with other ILDs are unclear. In...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632801/?tool=EBI |
| _version_ | 1798044661553561600 |
|---|---|
| author | Sofia A. Moll Mark G. J. P. Platenburg Anouk C. M. Platteel Adriane D. M. Vorselaars Montse Janssen Bonàs Raisa Kraaijvanger Claudia Roodenburg-Benschop Bob Meek Coline H. M. van Moorsel Jan C. Grutters |
| author_facet | Sofia A. Moll Mark G. J. P. Platenburg Anouk C. M. Platteel Adriane D. M. Vorselaars Montse Janssen Bonàs Raisa Kraaijvanger Claudia Roodenburg-Benschop Bob Meek Coline H. M. van Moorsel Jan C. Grutters |
| author_sort | Sofia A. Moll |
| collection | DOAJ |
| description | <h4>Background</h4> Serologic testing for autoantibodies is recommended in interstitial lung diseases (ILDs), as connective tissue diseases (CTDs) are an important secondary cause. Myositis antibodies are associated with CTD-ILD, but clinical associations with other ILDs are unclear. In this study, associations of myositis antibodies in various ILDs were evaluated. <h4>Methods</h4> 1463 ILD patients and 116 healthy subjects were screened for myositis antibodies with a line-blot assay on serum available at time of diagnosis. Additionally, bronchoalveolar lavage fluid (BALf) was analysed. <h4>Results</h4> A total of 394 patients demonstrated reactivity to at least one antibody, including anti-Ro52 (36.0%), anti-Mi-2β (17.3%) and anti-Jo-1 (10.9%). Anti-Jo-1 (OR 6.4; p<0.100) and anti-Ro52 (OR 6.0; p<0.001) were associated with CTD-ILD. Interestingly, anti-Mi-2β was associated with idiopathic pulmonary fibrosis (IPF; OR 5.3; p = 0.001) and hypersensitivity pneumonitis (HP; OR 5.9; p<0.001). Furthermore, anti-Mi-2β was strongly associated with a histological usual interstitial pneumonia (UIP) pattern (OR 6.5; p < 0.001). Moreover, anti-Mi-2β reactivity was identified in BALf and correlated with serum anti-Mi-2β (r = 0.64; p = 0.002). No differences were found in survival rates between ILD patients with and without serum Mi-2β reactivity (hazard ratio 0.835; 95% CI 0.442–1.575; p = 0.577). <h4>Conclusion</h4> In conclusion, novel associations of antibody Mi-2β with fibrotic ILD were found. Furthermore, serum anti-Mi-2β was associated with a histological UIP pattern and presence of anti-Mi-2β in BALf. Possibly, anti-Mi-2β could be implemented as a future diagnostic biomarker for fibrotic ILD. |
| first_indexed | 2024-04-11T23:07:52Z |
| format | Article |
| id | doaj.art-aa26dc504bac4744b8479c8d671dbba4 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-11T23:07:52Z |
| publishDate | 2022-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-aa26dc504bac4744b8479c8d671dbba42022-12-22T03:57:57ZengPublic Library of Science (PLoS)PLoS ONE1932-62032022-01-011711Prevalence and clinical associations of myositis antibodies in a large cohort of interstitial lung diseasesSofia A. MollMark G. J. P. PlatenburgAnouk C. M. PlatteelAdriane D. M. VorselaarsMontse Janssen BonàsRaisa KraaijvangerClaudia Roodenburg-BenschopBob MeekColine H. M. van MoorselJan C. Grutters<h4>Background</h4> Serologic testing for autoantibodies is recommended in interstitial lung diseases (ILDs), as connective tissue diseases (CTDs) are an important secondary cause. Myositis antibodies are associated with CTD-ILD, but clinical associations with other ILDs are unclear. In this study, associations of myositis antibodies in various ILDs were evaluated. <h4>Methods</h4> 1463 ILD patients and 116 healthy subjects were screened for myositis antibodies with a line-blot assay on serum available at time of diagnosis. Additionally, bronchoalveolar lavage fluid (BALf) was analysed. <h4>Results</h4> A total of 394 patients demonstrated reactivity to at least one antibody, including anti-Ro52 (36.0%), anti-Mi-2β (17.3%) and anti-Jo-1 (10.9%). Anti-Jo-1 (OR 6.4; p<0.100) and anti-Ro52 (OR 6.0; p<0.001) were associated with CTD-ILD. Interestingly, anti-Mi-2β was associated with idiopathic pulmonary fibrosis (IPF; OR 5.3; p = 0.001) and hypersensitivity pneumonitis (HP; OR 5.9; p<0.001). Furthermore, anti-Mi-2β was strongly associated with a histological usual interstitial pneumonia (UIP) pattern (OR 6.5; p < 0.001). Moreover, anti-Mi-2β reactivity was identified in BALf and correlated with serum anti-Mi-2β (r = 0.64; p = 0.002). No differences were found in survival rates between ILD patients with and without serum Mi-2β reactivity (hazard ratio 0.835; 95% CI 0.442–1.575; p = 0.577). <h4>Conclusion</h4> In conclusion, novel associations of antibody Mi-2β with fibrotic ILD were found. Furthermore, serum anti-Mi-2β was associated with a histological UIP pattern and presence of anti-Mi-2β in BALf. Possibly, anti-Mi-2β could be implemented as a future diagnostic biomarker for fibrotic ILD.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632801/?tool=EBI |
| spellingShingle | Sofia A. Moll Mark G. J. P. Platenburg Anouk C. M. Platteel Adriane D. M. Vorselaars Montse Janssen Bonàs Raisa Kraaijvanger Claudia Roodenburg-Benschop Bob Meek Coline H. M. van Moorsel Jan C. Grutters Prevalence and clinical associations of myositis antibodies in a large cohort of interstitial lung diseases PLoS ONE |
| title | Prevalence and clinical associations of myositis antibodies in a large cohort of interstitial lung diseases |
| title_full | Prevalence and clinical associations of myositis antibodies in a large cohort of interstitial lung diseases |
| title_fullStr | Prevalence and clinical associations of myositis antibodies in a large cohort of interstitial lung diseases |
| title_full_unstemmed | Prevalence and clinical associations of myositis antibodies in a large cohort of interstitial lung diseases |
| title_short | Prevalence and clinical associations of myositis antibodies in a large cohort of interstitial lung diseases |
| title_sort | prevalence and clinical associations of myositis antibodies in a large cohort of interstitial lung diseases |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632801/?tool=EBI |
| work_keys_str_mv | AT sofiaamoll prevalenceandclinicalassociationsofmyositisantibodiesinalargecohortofinterstitiallungdiseases AT markgjpplatenburg prevalenceandclinicalassociationsofmyositisantibodiesinalargecohortofinterstitiallungdiseases AT anoukcmplatteel prevalenceandclinicalassociationsofmyositisantibodiesinalargecohortofinterstitiallungdiseases AT adrianedmvorselaars prevalenceandclinicalassociationsofmyositisantibodiesinalargecohortofinterstitiallungdiseases AT montsejanssenbonas prevalenceandclinicalassociationsofmyositisantibodiesinalargecohortofinterstitiallungdiseases AT raisakraaijvanger prevalenceandclinicalassociationsofmyositisantibodiesinalargecohortofinterstitiallungdiseases AT claudiaroodenburgbenschop prevalenceandclinicalassociationsofmyositisantibodiesinalargecohortofinterstitiallungdiseases AT bobmeek prevalenceandclinicalassociationsofmyositisantibodiesinalargecohortofinterstitiallungdiseases AT colinehmvanmoorsel prevalenceandclinicalassociationsofmyositisantibodiesinalargecohortofinterstitiallungdiseases AT jancgrutters prevalenceandclinicalassociationsofmyositisantibodiesinalargecohortofinterstitiallungdiseases |